Triomics, a pioneering generative AI startup, has raised $15 million in Series A funding to accelerate its mission of automating cancer clinical trials matching. Founded by former MIT biotech researcher Sarim Khan and AI scientist Hrituraj Singh, Triomics aims to drastically reduce the time it takes for doctors to match patients with suitable trials, addressing a critical gap in cancer care.
Despite the abundance of clinical trials, only a small fraction of eligible patients enroll, largely due to the time-consuming process of trial matching. Triomics’ generative AI technology promises to streamline this process, enabling oncologists to swiftly identify relevant trials tailored to each patient’s unique profile.
The company’s platform, OncoLLM, leverages advances in generative AI and large language models (LLMs) to extract pertinent data from electronic health records (EHR), enabling rapid identification of suitable trials. By automating this labor-intensive task, Triomics aims to empower medical staff to efficiently match patients with trials, potentially saving lives and advancing cancer research.
Since its inception in 2021, Triomics has gained significant traction, with six cancer centers and hospitals actively utilizing or piloting its platform. With the Series A funding from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, Triomics plans to further develop its platform and expand its customer base, doubling its reach by the end of the year.
While Triomics initially focuses on clinical trials matching, Khan emphasizes that the platform offers broader applications beyond this scope. Medical staff can leverage OncoLLM for various use cases, from preparing for patient visits to submitting cancer data to regulatory agencies. Triomics aims to become a comprehensive solution for cancer centers, leveraging AI to enhance efficiency and improve patient outcomes.
While Triomics faces competition in the AI clinical trial matching space, Khan believes that its focus on processing large datasets specifically for cancer centers sets it apart. With its innovative approach and strong investor backing, Triomics is poised to make a significant impact in the fight against cancer.
